Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan led to greater improvements in hemoglobin compared with eculizumab among patients with paroxysmal ...
The paroxysmal nocturnal hemoglobinuria market is witnessing robust growth, driven by increasing disease awareness, improved diagnostics, and the expanding adoption of targeted therapies. The approval ...
Clone size and symptom burden dictate how often patients with PNH require follow-up. Hematology assessments during routine visits should include flow cytometry, CBC, D-dimer levels, and serum ferritin ...
These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance. In ...
Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Patients with paroxysmal nocturnal hemoglobinuria who received iptacopan vs. standard therapy had ...
BOSTON, April 5, 2011 (GLOBE NEWSWIRE) -- Oncology Care Live (www.OncologyCarelive.com ), the live online oncology congress, today announced that Michael J. Borowitz ...
We have recently had the opportunity of studying a case of march hemoglobinuria in a young woman in whom attacks were precipitated by short walks. The present communication describes the clinical and ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...
AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results